Exelixis (EXEL)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$72.75+0.61%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · EXEL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 3.0% |
| Our one-year growth estimate | diamond | 12.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 9.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
EXEL — litigation filed
Dated 2026-08-31
Other Events. On August 31, 2026, Exelixis, inc. (Exelixis) announced that the U.S. Court of Appeals for the Federal Circuit (Court of Appeals) issued a decision in Exelixis, Inc. v. MSN Laboratories Private Limited et al. , Appeal No. 25-1236, affirming the judgment of the U.S. District Court for the District of Delaware that U.S. Patent Nos. 11,091,439, 11,091,440 and 11,098,015 are not invalid. The Court of Appeals also dismissed as moot MSN’s appeal relating to the validity of U.S. Patent…
Why it matters: This Phase 3 trial tests zanzalintinib with nivolumab against sunitinib. Results test the drug in a new cancer type.
Watch forTopline results meet the trial's main goals for progression-free survival or response rate.
Also watch forTopline results miss both main goals, or the company reports a delay past the stated second-half 2026 window.
Why it matters: Cabozantinib is the current revenue base. U.S. product sales rose from $555.0 million in Q1 to $604.9 million in Q3.
Supportive ifU.S. cabozantinib product revenue stays above $600 million in the next reported quarter.
Worry ifU.S. cabozantinib product revenue falls below $573.0 million, the Q2 2026 level.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$115 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $282 loss on $10,000 · 2.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,259 loss on $10,000 · 12.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.